Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors

OncoImmunology

Volumn 5, Issue 5, 2016, Pages

  Tsai, Alexander K ^a   Davila, Eduardo ^a,b  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Adoptive transfer; Cancer therapy; Cell vehicle; Drug delivery; Genetic engineering; T cell

Indexed keywords

IMMUNOTHERAPY; T LYMPHOCYTE; THEORETICAL MODEL;

EID: 84964319366     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1122158     Document Type: Review

References (84)

1. M.A.Dao, K.A.Pepper, J.A.Nolta. Long-term cytokine production from engineered primary human stromal cells influences human hematopoiesis in an in vivo xenograft model. Stem Cells 1997; 15:443-54; PMID:9402657; http://dx.doi.org/10.1002/stem.150443
2. K.Liu, S.A.Rosenberg. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity. J Immunol 2001; 167:6356-65; PMID:11714800; http://dx.doi.org/10.4049/jimmunol.167.11.6356
3. K.Liu, S.A.Rosenberg. Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent. J Immunother 2003; 26:190-201; PMID:12806273; http://dx.doi.org/10.1097/00002371-200305000-00003
4. T.Meyerrose, S.Olson, S.Pontow, S.Kalomoiris, Y.Jung, G.Annett, G.Bauer, J.A.Nolta. Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors. Adv Drug Deliv Rev 2010; 62:1167-74; PMID:20920540; http://dx.doi.org/10.1016/j.addr.2010.09.013
5. K.W.Liechty, T.C.MacKenzie, A.F.Shaaban, A.Radu, A.M.Moseley, R.Deans, D.R.Marshak, A.W.Flake. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 2000; 6:1282-6; PMID:11062543; http://dx.doi.org/10.1038/81395
6. L.Sanz, M.Compte, I.Guijarro-Munoz, L.Alvarez-Vallina. Non-hematopoietic stem cells as factories for in vivo therapeutic protein production. Gene Ther 2012; 19:1-7; PMID:21562594; http://dx.doi.org/10.1038/gt.2011.68
7. J.A.Ankrum, J.F.Ong, J.M.Karp. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol 2014; 32:252-60; PMID:24561556; http://dx.doi.org/10.1038/nbt.2816
8. J.C.Roth, D.T.Curiel, L.Pereboeva. Cell vehicle targeting strategies. Gene Ther 2008; 15:716-29; PMID:18369326; http://dx.doi.org/10.1038/gt.2008.38
9. K.Shah. Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev 2012; 64:739-48; PMID:21740940; http://dx.doi.org/10.1016/j.addr.2011.06.010
10. M.Khorashadizadeh, M.Soleimani, H.Khanahmad, A.Fallah, M.Naderi, M.Khorramizadeh. Bypassing the need for pre-sensitization of cancer cells for anticancer TRAIL therapy with secretion of novel cell penetrable form of Smac from hA-MSCs as cellular delivery vehicle. Tumour Biol 2015; 36:4213-21; PMID:25586349; http://dx.doi.org/10.1007/s13277-015-3058-2
11. A.Z.Dudek. Endothelial lineage cell as a vehicle for systemic delivery of cancer gene therapy. Transl Res 2010; 156:136-46; PMID:20801410; http://dx.doi.org/10.1016/j.trsl.2010.07.003
12. R.Z.Lin, A.Dreyzin, K.Aamodt, D.Li, S.C.Jaminet, A.C.Dudley, J.M.Melero-Martin. Induction of erythropoiesis using human vascular networks genetically engineered for controlled erythropoietin release. Blood 2011; 118:5420-8; PMID:21937702; http://dx.doi.org/10.1182/blood-2011-08-372946
13. M.Compte, V.Alonso-Camino, P.Santos-Valle, A.M.Cuesta, D.Sanchez-Martin, M.R.Lopez, J.L.Vicario, C.Salas, L.Sanz, L.Alvarez-Vallina. Factory neovessels: engineered human blood vessels secreting therapeutic proteins as a new drug delivery system. Gene Ther 2010; 17:745-51; PMID:20336155; http://dx.doi.org/10.1038/gt.2010.33
14. H.Neumann. Microglia: a cellular vehicle for CNS gene therapy. J Clin Invest 2006; 116:2857-60; PMID:17080190; http://dx.doi.org/10.1172/JCI30230
15. S.Lee, K.Margolin. Tumor-infiltrating lymphocytes in melanoma. Curr Oncol Rep 2012; 14:468-74; PMID:22878966; http://dx.doi.org/10.1007/s11912-012-0257-5
16. M.H.Kershaw, J.A.Westwood, C.Y.Slaney, P.K.Darcy. Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunol 2014; 3:e16; PMID:25505964; http://dx.doi.org/10.1038/cti.2014.7
17. M.Sadelain, R.Brentjens, I.Riviere. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009; 21:215-23; PMID:19327974; http://dx.doi.org/10.1016/j.coi.2009.02.009
18. M.Sadelain, R.Brentjens, I.Riviere. The basic principles of chimeric antigen receptor design. Cancer Discov 2013; 3:388-98; PMID:23550147; http://dx.doi.org/10.1158/2159-8290.CD-12-0548
19. A.P.Rapoport, E.A.Stadtmauer, G.K.Binder-Scholl, O.Goloubeva, D.T.Vogl, S.F.Lacey, A.Z.Badros, A.Garfall, B.Weiss, J.Finklestein et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med 2015; 21:914-21; PMID:26193344; http://dx.doi.org/10.1038/nm.3910
20. Q.Zhang, H.Li, J.Yang, L.Li, B.Zhang, J.Li, J.Zheng. Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer. Curr Gene Ther 2013; 13:65-70; PMID:23256743; http://dx.doi.org/10.2174/156652313804806570
21. M.Kalos, C.H.June. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 2013; 39:49-60; PMID:23890063; http://dx.doi.org/10.1016/j.immuni.2013.07.002
22. R.A.Morgan, J.C.Yang, M.Kitano, M.E.Dudley, C.M.Laurencot, S.A.Rosenberg. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18:843-51; PMID:20179677; http://dx.doi.org/10.1038/mt.2010.24
23. R.A.Morgan, N.Chinnasamy, D.Abate-Daga, A.Gros, P.F.Robbins, Z.Zheng, M.E.Dudley, S.A.Feldman, J.C.Yang, R.M.Sherry et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013; 36:133-51; PMID:23377668; http://dx.doi.org/10.1097/CJI.0b013e3182829903
24. G.P.Linette, E.A.Stadtmauer, M.V.Maus, A.P.Rapoport, B.L.Levine, L.Emery, L.Litzky, A.Bagg, B.M.Carreno, P.J.Cimino et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013; 122:863-71; PMID:23770775; http://dx.doi.org/10.1182/blood-2013-03-490565
25. D.L.Porter, B.L.Levine, M.Kalos, A.Bagg, C.H.June. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-33; PMID:21830940; http://dx.doi.org/10.1056/NEJMoa1103849
26. M.Kalos, B.L.Levine, D.L.Porter, S.Katz, S.A.Grupp, A.Bagg, C.H.June. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95ra73; PMID:21832238; http://dx.doi.org/10.1126/scitranslmed.3002842
27. J.N.Kochenderfer, M.E.Dudley, S.A.Feldman, W.H.Wilson, D.E.Spaner, I.Maric, M.Stetler-Stevenson, G.Q.Phan, M.S.Hughes, R.M.Sherry et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119:2709-20; PMID:22160384; http://dx.doi.org/10.1182/blood-2011-10-384388
28. R.J.Brentjens, M.L.Davila, I.Riviere, J.Park, X.Wang, L.G.Cowell, S.Bartido, J.Stefanski, C.Taylor, M.Olszewska et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5:177ra38; PMID:23515080; http://dx.doi.org/10.1126/scitranslmed.3005930
29. G.Q.Phan, S.A.Rosenberg. Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. Cancer Control 2013; 20:289-97; PMID:24077405
30. S.A.Rosenberg, N.P.Restifo, J.C.Yang, R.A.Morgan, M.E.Dudley. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308; PMID:18354418; http://dx.doi.org/10.1038/nrc2355
31. S.A.Rosenberg. Cell transfer immunotherapy for metastatic solid cancer–what clinicians need to know. Nat Rev Clin Oncol 2011; 8:577-85; PMID:21808266; http://dx.doi.org/10.1038/nrclinonc.2011.116
32. B.Engelhardt, R.M.Ransohoff. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol 2012; 33:579-89; PMID:22926201; http://dx.doi.org/10.1016/j.it.2012.07.004
33. G.T.Motz, G.Coukos. Deciphering and reversing tumor immune suppression. Immunity 2013; 39:61-73; PMID:23890064; http://dx.doi.org/10.1016/j.immuni.2013.07.005
34. C.Bouzin, A.Brouet, J.De Vriese, J.Dewever, O.Feron. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J Immunol 2007; 178:1505-11; PMID:17237399; http://dx.doi.org/10.4049/jimmunol.178.3.1505
35. K.Franciszkiewicz, A.Boissonnas, M.Boutet, C.Combadiere, F.Mami-Chouaib. Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res 2012; 72:6325-32; PMID:23222302; http://dx.doi.org/10.1158/0008-5472.CAN-12-2027
36. C.Oelkrug, J.M.Ramage. Enhancement of T cell recruitment and infiltration into tumours. Clin Exp Immunol 2014; 178:1-8; PMID:24828133; http://dx.doi.org/10.1111/cei.12382
37. M.Sata, K.Walsh. TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med 1998; 4:415-20; PMID:9546786; http://dx.doi.org/10.1038/nm0498-415
38. N.Rodig, T.Ryan, J.A.Allen, H.Pang, N.Grabie, T.Chernova, E.A.Greenfield, S.C.Liang, A.H.Sharpe, A.H.Lichtman et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol 2003; 33:3117-26; PMID:14579280; http://dx.doi.org/10.1002/eji.200324270
39. D.I.Gabrilovich, S.Nagaraj. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx.doi.org/10.1038/nri2506
40. N.B.Hao, M.H.Lu, Y.H.Fan, Y.L.Cao, Z.R.Zhang, S.M.Yang. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol 2012; 2012:948098; PMID:22778768; http://dx.doi.org/10.1155/2012/948098
41. Y.Ma, G.V.Shurin, Z.Peiyuan, M.R.Shurin. Dendritic cells in the cancer microenvironment. J Cancer 2013; 4:36-44; PMID:23386903; http://dx.doi.org/10.7150/jca.5046
42. B.Burkholder, R.Y.Huang, R.Burgess, S.Luo, V.S.Jones, W.Zhang, Z.Q.Lv, C.Y.Gao, B.L.Wang, Y.M.Zhang et al. Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta 2014; 1845:182-201; PMID:24440852; http://dx.doi.org/10.1016/j.bbcan.2014.01.004
43. B.E.Lippitz. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013; 14:e218–28; PMID:23639322; http://dx.doi.org/10.1016/S1470-2045(12)70582-X
44. G.J.Freeman, A.J.Long, Y.Iwai, K.Bourque, T.Chernova, H.Nishimura, L.J.Fitz, N.Malenkovich, T.Okazaki, M.C.Byrne et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027-34; PMID:11015443; http://dx.doi.org/10.1084/jem.192.7.1027
45. D.M.Pardoll. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
46. C.Quintarelli, J.F.Vera, B.Savoldo, G.M.Giordano Attianese, M.Pule, A.E.Foster, H.E.Heslop, C.M.Rooney, M.K.Brenner, G.Dotti. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 2007; 110:2793-802; PMID:17638856; http://dx.doi.org/10.1182/blood-2007-02-072843
47. B.Heemskerk, K.Liu, M.E.Dudley, L.A.Johnson, A.Kaiser, S.Downey, Z.Zheng, T.E.Shelton, K.Matsuda, P.F.Robbins et al. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther 2008; 19:496-510; PMID:18444786; http://dx.doi.org/10.1089/hum.2007.0171
48. C.A.Klebanoff, S.E.Finkelstein, D.R.Surman, M.K.Lichtman, L.Gattinoni, M.R.Theoret, N.Grewal, P.J.Spiess, P.A.Antony, D.C.Palmer et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A 2004; 101:1969-74; PMID:14762166; http://dx.doi.org/10.1073/pnas.0307298101
49. C.Hsu, M.S.Hughes, Z.Zheng, R.B.Bray, S.A.Rosenberg, R.A.Morgan. Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. J Immunol 2005; 175:7226-34; PMID:16301627; http://dx.doi.org/10.4049/jimmunol.175.11.7226
50. C.Hsu, S.A.Jones, C.J.Cohen, Z.Zheng, K.Kerstann, J.Zhou, P.F.Robbins, P.D.Peng, X.Shen, T.J.Gomes et al. Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood 2007; 109:5168-77; PMID:17353346; http://dx.doi.org/10.1182/blood-2006-06-029173
51. V.Hoyos, B.Savoldo, C.Quintarelli, A.Mahendravada, M.Zhang, J.Vera, H.E.Heslop, C.M.Rooney, M.K.Brenner, G.Dotti. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010; 24:1160-70; PMID:20428207; http://dx.doi.org/10.1038/leu.2010.75
52. H.J.Wagner, C.M.Bollard, S.Vigouroux, M.H.Huls, R.Anderson, H.G.Prentice, M.K.Brenner, H.E.Heslop, C.M.Rooney. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther 2004; 11:81-91; PMID:14685154; http://dx.doi.org/10.1038/sj.cgt.7700664
53. S.P.Kerkar, P.Muranski, A.Kaiser, A.Boni, L.Sanchez-Perez, Z.Yu, D.C.Palmer, R.N.Reger, Z.A.Borman, L.Zhang et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res 2010; 70:6725-34; PMID:20647327; http://dx.doi.org/10.1158/0008-5472.CAN-10-0735
54. D.Chinnasamy, Z.Yu, S.P.Kerkar, L.Zhang, R.A.Morgan, N.P.Restifo, S.A.Rosenberg. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res 2012; 18:1672-83; PMID:22291136; http://dx.doi.org/10.1158/1078-0432.CCR-11-3050
55. L.Zhang, S.P.Kerkar, Z.Yu, Z.Zheng, S.Yang, N.P.Restifo, S.A.Rosenberg, R.A.Morgan. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther 2011; 19:751-9; PMID:21285960; http://dx.doi.org/10.1038/mt.2010.313
56. L.Zhang, S.A.Feldman, Z.Zheng, N.Chinnasamy, H.Xu, A.V.Nahvi, M.E.Dudley, S.A.Rosenberg, R.A.Morgan. Evaluation of gamma-retroviral vectors that mediate the inducible expression of IL-12 for clinical application. J Immunother 2012; 35:430-9; PMID:22576348; http://dx.doi.org/10.1097/CJI.0b013e31825898e8
57. H.J.Pegram, J.C.Lee, E.G.Hayman, G.H.Imperato, T.F.Tedder, M.Sadelain, R.J.Brentjens. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012; 119:4133-41; PMID:22354001; http://dx.doi.org/10.1182/blood-2011-12-400044
58. M.Koneru, T.J.Purdon, D.Spriggs, S.Koneru, R.J.Brentjens. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors. Oncoimmunology 2015; 4:e994446; PMID:25949921; http://dx.doi.org/10.4161/2162402X.2014.994446
59. H.J.Pegram, T.J.Purdon, D.G.van Leeuwen, K.J.Curran, S.A.Giralt, J.N.Barker, R.J.Brentjens. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia. Leukemia 2015; 29:415-22; PMID:25005243; http://dx.doi.org/10.1038/leu.2014.215
60. L.Zhang, R.A.Morgan, J.D.Beane, Z.Zheng, M.E.Dudley, S.H.Kassim, A.V.Nahvi, L.T.Ngo, R.M.Sherry, G.Q.Phan et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res 2015; 21:2278-88; PMID:25695689; http://dx.doi.org/10.1158/1078-0432.CCR-14-2085
61. J.C.Markley, M.Sadelain. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 2010; 115:3508-19; PMID:20190192; http://dx.doi.org/10.1182/blood-2009-09-241398
62. M.Compte, B.Blanco, F.Serrano, A.M.Cuesta, L.Sanz, A.Bernad, P.Holliger, L.Alvarez-Vallina. Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther 2007; 14:380-8; PMID:17218946; http://dx.doi.org/10.1038/sj.cgt.7701021
63. K.Iwahori, S.Kakarla, M.P.Velasquez, F.Yu, Z.Yi, C.Gerken, X.T.Song, S.Gottschalk. Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Mol Ther 2015; 23:171-8; PMID:25142939; http://dx.doi.org/10.1038/mt.2014.156
64. G.Rahir, M.Moser. Tumor microenvironment and lymphocyte infiltration. Cancer Immunol Immunother 2012; 61:751-9; PMID:22488275; http://dx.doi.org/10.1007/s00262-012-1253-1
65. M.J.Carson, J.M.Doose, B.Melchior, C.D.Schmid, C.C.Ploix. CNS immune privilege: hiding in plain sight. Immunol Rev 2006; 213:48-65; PMID:16972896; http://dx.doi.org/10.1111/j.1600-065X.2006.00441.x
66. M.Fijak, A.Meinhardt. The testis in immune privilege. Immunol Rev 2006; 213:66-81; PMID:16972897; http://dx.doi.org/10.1111/j.1600-065X.2006.00438.x
67. S.Cose. T-cell migration: a naive paradigm? Immunology 2007; 120:1-7; PMID:17233737; http://dx.doi.org/10.1111/j.1365-2567.2006.02511.x
68. F.Kratz, A.Warnecke. Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems. J Control Release 2012; 164:221-35; PMID:22705248; http://dx.doi.org/10.1016/j.jconrel.2012.05.045
69. E.Hooijberg, A.Q.Bakker, J.J.Ruizendaal, H.Spits. NFAT-controlled expression of GFP permits visualization and isolation of antigen-stimulated primary human T cells. Blood 2000; 96:459-66; PMID:10887106
70. A.H.Rook, G.S.Wood, E.K.Yoo, R.Elenitsas, D.M.Kao, M.L.Sherman, W.K.Witmer, K.A.Rockwell, R.B.Shane, S.R.Lessin et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999; 94:902-8; PMID:10419880
71. M.Duvic, M.L.Sherman, G.S.Wood, T.M.Kuzel, E.Olsen, F.Foss, R.J.Laliberte, J.L.Ryan, K.Zonno, A.H.Rook. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. J Am Acad Dermatol 2006; 55:807-13; PMID:17052486; PMID:12391195; http://dx.doi.org/10.1016/j.jaad.2006.06.038
72. A.R.Almeida, N.Legrand, M.Papiernik, A.A.Freitas. Homeostasis of peripheral CD4+ T cells: IL-2R α and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. J Immunol 2002; 169:4850-60; PMID:12391195; http://dx.doi.org/10.4049/jimmunol.169.9.4850
73. M.Koneru, R.O'Cearbhaill, S.Pendharkar, D.R.Spriggs, R.J.Brentjens. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med 2015; 13:102; PMID:25890361; http://dx.doi.org/10.1186/s12967-015-0460-x
74. M.H.Kershaw, G.Wang, J.A.Westwood, R.K.Pachynski, H.L.Tiffany, F.M.Marincola, E.Wang, H.A.Young, P.M.Murphy, P.Hwu. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther 2002; 13:1971-80; PMID:12427307; http://dx.doi.org/10.1089/10430340260355374
75. J.A.Craddock, A.Lu, A.Bear, M.Pule, M.K.Brenner, C.M.Rooney, A.E.Foster. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother 2010; 33:780-8; PMID:20842059; http://dx.doi.org/10.1097/CJI.0b013e3181ee6675
76. A.E.Foster, G.Dotti, A.Lu, M.Khalil, M.K.Brenner, H.E.Heslop, C.M.Rooney, C.M.Bollard. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-β receptor. J Immunother 2008; 31:500-5; PMID:18463534; http://dx.doi.org/10.1097/CJI.0b013e318177092b
77. G.M.Bendle, C.Linnemann, L.Bies, J.Y.Song, T.N.Schumacher. Blockade of TGF-β signaling greatly enhances the efficacy of TCR gene therapy of cancer. J Immunol 2013; 191:3232-9; PMID:23940272; http://dx.doi.org/10.4049/jimmunol.1301270
78. H.Yu, D.Pardoll, R.Jove. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798-809; PMID:19851315; http://dx.doi.org/10.1038/nrc2734
79. C.Rebe, F.Vegran, H.Berger, F.Ghiringhelli. STAT3 activation: A key factor in tumor immunoescape. Jak-Stat 2013; 2:e23010; PMID:24058791; http://dx.doi.org/10.4161/jkst.23010
80. P.Sansone, J.Bromberg. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 2012; 30:1005-14; PMID:22355058; http://dx.doi.org/10.1200/JCO.2010.31.8907
81. S.Kaczanowska, A.M.Joseph, E.Davila. TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol 2013; 93:847-63; PMID:23475577; http://dx.doi.org/10.1189/jlb.1012501
82. D.Geng, S.Kaczanowska, A.Tsai, K.Younger, A.Ochoa, A.P.Rapoport, S.Ostrand-Rosenberg, E.Davila. TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity. Cancer Res 2015; 75:1959-71; PMID:25795705; http://dx.doi.org/10.1158/0008-5472.CAN-14-2467
83. A.Di Stasi, S.K.Tey, G.Dotti, Y.Fujita, A.Kennedy-Nasser, C.Martinez, K.Straathof, E.Liu, A.G.Durett, B.Grilley et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011; 365:1673-83; PMID:22047558; http://dx.doi.org/10.1056/NEJMoa1106152
84. H.D.Bae, K.Lee. On employing a translationally controlled tumor protein-derived protein transduction domain analog for transmucosal delivery of drugs. J Control Release 2013; 170:358-64; PMID:23791976; http://dx.doi.org/10.1016/j.jconrel.2013.06.010